The Hospital Value-Based Purchasing Program did not result in meaningful improvements in clinical process or patient experience measures during its first four years, because performance improved similarly for hospitals not exposed to the program, according to a study reported last week in the New England Journal of Medicine. The program was associated with reduced mortality among patients admitted for pneumonia, but not among patients admitted for heart attack or heart failure. Nancy Foster, AHA vice president for quality and patient safety policy, said the findings “should not be surprising for two important reasons. First, the measures used in the VBP program, especially those used in the first few years, had been publicly reported for several years. Many of the improvements that could be achieved had already occurred. Second, hospitals view the inclusion of a measure in the Hospital VBP program as a strong signal from Medicare that high performance on the measure is important. Thus, hospitals seek to achieve high levels of performance on the chosen measures regardless of whether they are subject to a payment penalty or not.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services released a memo Dec. 16 announcing the agency’s intent to conduct a voluntary pilot in 2026, called the…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Headline
The Medicare Payment Advisory Commission Dec. 4 and 5 discussed draft payment update recommendations for 2027, which the commission will vote on in January.…
Headline
The House Dec. 1 passed the Hospital Inpatient Services Modernization Act (H.R. 4313), legislation extending certain Medicare waivers authorizing the hospital-…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 1 that it intends to expand the Inpatient Rehabilitation Facility Review Choice Demonstration…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…